Cancer and Immunotherapy · global
Personalized mRNA Cancer Vaccine Reports Phase 3 Success, Reducing the Risk of Melanoma Recurrence After Surgery
A vaccine tailored to each patient’s tumor mutations, combined with immunotherapy, improved recurrence-free and distant metastasis-free survival in a trial involving more than 1,000 participants. However, the announcement summarizes an interim analysis; the magnitude of the benefit and long-term survival results remain to be disclosed.
For patients with melanoma, the risk of recurrence does not disappear after surgical removal of the tumor. Helping the immune system continue to recognize cancer cells is an important challenge in treatment after surgery. On August 19, 2026, Merck and Moderna announced that the personalized mRNA therapy intismeran autogene, combined with the immunotherapy drug pembrolizumab, improved recurrence-free survival and distant metastasis-free survival in a Phase 3 trial, providing key clinical evidence for cancer vaccines designed around individual tumors.
The global randomized, double-blind trial, named INTerpath-001, enrolled 1,137 patients with completely resected stage IIB to IV cutaneous melanoma. Participants were assigned in a two-to-one ratio to the combination therapy or pembrolizumab plus placebo. According to the companies’ announcement, a prespecified interim analysis showed statistically significant and clinically meaningful improvements in both the primary endpoint and the key secondary endpoint with the combination therapy.
The “vaccine” here is a treatment designed for patients who already have cancer. Researchers select recognition cues from each patient’s tumor mutations to create mRNA that can encode up to 34 neoantigens. These neoantigens are molecular features arising from tumor mutations; the therapy aims to guide T cells to recognize cancer cells by prompting the body to produce and present these features. Pembrolizumab, administered in combination, blocks PD-1 immune suppression signals. The two treatments address target recognition and the removal of immune suppression, respectively.
According to the trial design summarized by The ASCO Post, intismeran is administered once every three weeks for up to nine doses, while pembrolizumab is administered once every six weeks for up to nine cycles. Recurrence-free survival measures the time from randomization to cancer recurrence or death from any cause. Meeting this endpoint therefore does not mean that an improvement in overall survival has been demonstrated. The trial will continue to follow overall survival and other outcomes.
The magnitude of the improvement is the most pressing question to clarify. Chemical & Engineering News noted that the companies had not released detailed data when they announced the results and planned to present them at an international medical meeting. The “49% reduction in the risk of recurrence or death” mentioned in the announcement comes from the five-year follow-up of an earlier Phase 2b trial and cannot be treated as a result of this Phase 3 trial. The hazard ratio, absolute benefit, and number of events in each group for this interim analysis still await clarification in the full data.
On safety, the companies said that no new safety signals emerged and that the overall profile was consistent with previous studies of the combination therapy, but the announcement did not yet provide a complete comparison of adverse events. According to the companies, this is the first positive Phase 3 result for a personalized neoantigen therapy and an mRNA cancer therapy, and they will next discuss an application with regulatory authorities. The result opens up new possibilities for melanoma treatment after surgery; whether the therapy can become a routine option still depends on support from complete efficacy and safety data and regulatory review.